-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Schizophrenia is a chronic and persistent disease that recurs and is currently one of the most important mental disorders leading to mental disability.
According to the latest Global Burden of Disease (GBD) report, approximately 21 million people worldwide suffer from schizophrenia, and the number of illnesses is on the rise.
Most of these patients live in low- and middle-income countries, and there are obvious treatments for schizophrenia in these countries.
insufficient.On March 27, Luye Pharmaceutical Group announced that my country's first self-developed new anti-schizophrenia drug-Rexinto® (Risperidone Microspheres for Injection (II)) was officially launched in China.
Rexinto® is a sustained-release microsphere preparation for injection.
It is injected intramuscularly once every two weeks.
It is used to treat acute and chronic schizophrenia and other various psychotic states with obvious positive and negative symptoms, which can reduce the Affective symptoms related to schizophrenia.Recinto® is developed based on Luye Pharma’s world-leading microsphere technology platform.
As China’s first innovative microsphere preparation with independent intellectual property rights and global registration, it is also the first self-developed second-generation long-acting injection of an antipsychotic drug in my country.
The drug’s launch is not only for about 10 million people with schizophrenia in China.
The patient's return to society brings new hope, and it also means that Luye Pharma's innovative microsphere technology research and development platform, which has been deeply cultivated for many years, has successfully achieved industrialization and demonstrated its global leadership.Many guidelines at home and abroad strongly recommend that long-acting injections are the first choice for improving patient compliance and recurrenceSchizophrenia is one of a group of common mental diseases that seriously impairs patients' living ability and social function.
The main difficulty in the treatment of schizophrenia is the recurrence of the disease caused by the patient's interruption of treatment or self-reduction of medication.
According to the data, 60% of patients with the first attack have poor medication compliance, and the recurrence rate within 5 years exceeds 80%.
Multiple recurrences lead to prolonged course of the disease, increase the difficulty of treatment, and greatly increase the cost of treatment.
From the perspective of global treatment concepts and trends, the use of long-acting preparations is one of the main methods for the treatment of schizophrenia.
Recommended by a number of domestic and foreign guidelines, long-acting preparations range from providing compliance & preventing recurrence to all stages of the entire disease course.
The 2014 APA guidelines recommend that long-acting preparations are recommended for patients who have relapsed due to poor compliance.
The 2011 BAP guidelines recommended that patients prefer to use long-acting preparations.
Patients with poor compliance or compliance issues and patients who relapse due to compliance are recommended to use long-acting preparations.
The 2017 CPA guidelines recommend that the use of long-acting preparations should be recommended when discussing the existence and use of long-acting preparations with patients and their families at all stages of the disease, including the critical period of 2-5 years.
In addition, in my country's "Expert Consensus on Long-acting Antipsychotic Injections for the Treatment of Schizophrenia", the second-generation antipsychotic long-acting injections are used as the first-line treatment strategy for patients with schizophrenia in the acute and maintenance phases. Professor Cai Jun, chief physician of the Mental Health Center affiliated to Shanghai Jiaotong University School of Medicine, pointed out: “Based on the characteristics of high recurrence of schizophrenia, we advocate the early use of long-acting injections at all stages of the disease course.
As the first independent research and development in my country, The second-generation antipsychotic long-acting injection, Rexinto® is further improved and upgraded on the basis of the existing commercially available long-acting injections.
It is suitable for the whole course of treatment of schizophrenia and provides patients with new treatment options.
"Innovative microsphere preparation to further improve the safety and compliance of schizophrenia treatmentIn recent years, the main treatment for schizophrenia has been drug therapy, usually combined with psychotherapy and social support.
Currently, alternative antipsychotic medications include oral medications or long-acting injections.
However, because oral drugs need to be taken on time and in the amount every day, some patients often cause fluctuations in their condition due to their own or objective factors, and a number of studies have shown that long-acting injections are more effective in reducing treatment interruption caused by treatment interruptions than oral dosage forms.
The probability of recurrence and re-hospitalization, improve patient compliance with treatment, prevent recurrence, and have higher safety.
Rexinto® is injected intramuscularly once every two weeks, which can significantly improve the compliance of oral antipsychotics, which is common in patients with schizophrenia.
Compared with oral preparations, the frequency of administration of Rexinto® is significantly reduced, which can effectively improve patients' missed or forgotten medication.
In addition, the blood concentration of Rexinto® in the body is stable, which reduces the difference between peaks and troughs of blood concentration compared with oral preparations, helps reduce the risk of dose-dependent side effects, and improves the safety of patients' medication.
Poor compliance and high recurrence are still the main problems and challenges in the treatment of schizophrenia.
"The treatment concept of schizophrenia has changed from controlling symptoms to improving cognition, promoting recovery, and finally returning patients to society.
In this process, improving patient compliance to prevent recurrence is the key to the treatment of schizophrenia.
" Shanghai Jiaotong Professor Cai Jun, chief physician of the Mental Health Center affiliated to the University School of Medicine, said: “Long-acting antipsychotics can significantly improve patient compliance compared with oral preparations, and are an important treatment strategy to prevent recurrence.
”
From the perspective of global treatment concepts and trends, the use of long-acting preparations is one of the main methods for the treatment of schizophrenia.
Recommended by a number of domestic and foreign guidelines, long-acting preparations range from providing compliance & preventing recurrence to all stages of the entire disease course.
The 2014 APA guidelines recommend that long-acting preparations are recommended for patients who have relapsed due to poor compliance.
The 2011 BAP guidelines recommended that patients prefer to use long-acting preparations.
Patients with poor compliance or compliance issues and patients who relapse due to compliance are recommended to use long-acting preparations.
The 2017 CPA guidelines recommend that the use of long-acting preparations should be recommended when discussing the existence and use of long-acting preparations with patients and their families at all stages of the disease, including the critical period of 2-5 years.
In addition, in my country's "Expert Consensus on Long-acting Antipsychotic Injections for the Treatment of Schizophrenia", the second-generation antipsychotic long-acting injections are used as the first-line treatment strategy for patients with schizophrenia in the acute and maintenance phases. Professor Cai Jun, chief physician of the Mental Health Center affiliated to Shanghai Jiaotong University School of Medicine, pointed out: “Based on the characteristics of high recurrence of schizophrenia, we advocate the early use of long-acting injections at all stages of the disease course.
As the first independent research and development in my country, The second-generation antipsychotic long-acting injection, Rexinto® is further improved and upgraded on the basis of the existing commercially available long-acting injections.
It is suitable for the whole course of treatment of schizophrenia and provides patients with new treatment options.
"Innovative microsphere preparation to further improve the safety and compliance of schizophrenia treatmentIn recent years, the main treatment for schizophrenia has been drug therapy, usually combined with psychotherapy and social support.
Currently, alternative antipsychotic medications include oral medications or long-acting injections.
However, because oral drugs need to be taken on time and in the amount every day, some patients often cause fluctuations in their condition due to their own or objective factors, and a number of studies have shown that long-acting injections are more effective in reducing treatment interruption caused by treatment interruptions than oral dosage forms.
The probability of recurrence and re-hospitalization, improve patient compliance with treatment, prevent recurrence, and have higher safety.
Rexinto® is injected intramuscularly once every two weeks, which can significantly improve the compliance of oral antipsychotics, which is common in patients with schizophrenia.
Compared with oral preparations, the frequency of administration of Rexinto® is significantly reduced, which can effectively improve patients' missed or forgotten medication.
In addition, the blood concentration of Rexinto® in the body is stable, which reduces the difference between peaks and troughs of blood concentration compared with oral preparations, helps reduce the risk of dose-dependent side effects, and improves the safety of patients' medication.
From the perspective of global treatment concepts and trends, the use of long-acting preparations is one of the main methods for the treatment of schizophrenia.
Recommended by a number of domestic and foreign guidelines, long-acting preparations range from providing compliance & preventing recurrence to all stages of the entire disease course.
The 2014 APA guidelines recommend that long-acting preparations are recommended for patients who have relapsed due to poor compliance.
The 2011 BAP guidelines recommended that patients prefer to use long-acting preparations.
Patients with poor compliance or compliance issues and patients who relapse due to compliance are recommended to use long-acting preparations.
The 2017 CPA guidelines recommend that the use of long-acting preparations should be recommended when discussing the existence and use of long-acting preparations with patients and their families at all stages of the disease, including the critical period of 2-5 years.
In addition, in my country's "Expert Consensus on Long-acting Antipsychotic Injections for the Treatment of Schizophrenia", the second-generation antipsychotic long-acting injections are used as the first-line treatment strategy for patients with schizophrenia in the acute and maintenance phases. Professor Cai Jun, chief physician of the Mental Health Center affiliated to Shanghai Jiaotong University School of Medicine, pointed out: “Based on the characteristics of high recurrence of schizophrenia, we advocate the early use of long-acting injections at all stages of the disease course.
As the first independent research and development in my country, The second-generation antipsychotic long-acting injection, Rexinto® is further improved and upgraded on the basis of the existing commercially available long-acting injections.
It is suitable for the whole course of treatment of schizophrenia and provides patients with new treatment options.
"Innovative microsphere preparation to further improve the safety and compliance of schizophrenia treatmentIn recent years, the main treatment for schizophrenia has been drug therapy, usually combined with psychotherapy and social support.
Currently, alternative antipsychotic medications include oral medications or long-acting injections.
However, because oral drugs need to be taken on time and in the amount every day, some patients often cause fluctuations in their condition due to their own or objective factors, and a number of studies have shown that long-acting injections are more effective in reducing treatment interruption caused by treatment interruptions than oral dosage forms.
The probability of recurrence and re-hospitalization, improve patient compliance with treatment, prevent recurrence, and have higher safety.
Rexinto® is injected intramuscularly once every two weeks, which can significantly improve the compliance of oral antipsychotics, which is common in patients with schizophrenia.
Compared with oral preparations, the frequency of administration of Rexinto® is significantly reduced, which can effectively improve patients' missed or forgotten medication.
In addition, the blood concentration of Rexinto® in the body is stable, which reduces the difference between peaks and troughs of blood concentration compared with oral preparations, helps reduce the risk of dose-dependent side effects, and improves the safety of patients' medication.
From the perspective of global treatment concepts and trends, the use of long-acting preparations is one of the main methods for the treatment of schizophrenia.
Recommended by a number of domestic and foreign guidelines, long-acting preparations range from providing compliance & preventing recurrence to all stages of the entire disease course.
The 2014 APA guidelines recommend that long-acting preparations are recommended for patients who have relapsed due to poor compliance.
The 2011 BAP guidelines recommended that patients prefer to use long-acting preparations.
Patients with poor compliance or compliance issues and patients who relapse due to compliance are recommended to use long-acting preparations.
The 2017 CPA guidelines recommend that the use of long-acting preparations should be recommended when discussing the existence and use of long-acting preparations with patients and their families at all stages of the disease, including the critical period of 2-5 years.
In addition, in my country's "Expert Consensus on Long-acting Antipsychotic Injections for the Treatment of Schizophrenia", the second-generation antipsychotic long-acting injections are used as the first-line treatment strategy for patients with schizophrenia in the acute and maintenance phases.
From the perspective of global treatment concepts and trends, the use of long-acting preparations is one of the main methods for the treatment of schizophrenia.
Recommended by a number of domestic and foreign guidelines, long-acting preparations range from providing compliance & preventing recurrence to all stages of the entire disease course.
The 2014 APA guidelines recommend that long-acting preparations are recommended for patients who have relapsed due to poor compliance.
The 2011 BAP guidelines recommended that patients prefer to use long-acting preparations.
Patients with poor compliance or compliance issues and patients who relapse due to compliance are recommended to use long-acting preparations.
The 2017 CPA guidelines recommend that the use of long-acting preparations should be recommended when discussing the existence and use of long-acting preparations with patients and their families at all stages of the disease, including the critical period of 2-5 years.
In addition, in my country's "Expert Consensus on Long-acting Antipsychotic Injections for the Treatment of Schizophrenia", the second-generation antipsychotic long-acting injections are used as the first-line treatment strategy for patients with schizophrenia in the acute and maintenance phases.
From the perspective of global treatment concepts and trends, the use of long-acting preparations is one of the main methods for the treatment of schizophrenia.
Recommended by a number of domestic and foreign guidelines, long-acting preparations range from providing compliance & preventing recurrence to all stages of the entire disease course.
The 2014 APA guidelines recommend that long-acting preparations are recommended for patients who have relapsed due to poor compliance.
The 2011 BAP guidelines recommended that patients prefer to use long-acting preparations.
Patients with poor compliance or compliance issues and patients who relapse due to compliance are recommended to use long-acting preparations.
The 2017 CPA guidelines recommend that the use of long-acting preparations should be recommended when discussing the existence and use of long-acting preparations with patients and their families at all stages of the disease, including the critical period of 2-5 years.
In addition, in my country's "Expert Consensus on Long-acting Antipsychotic Injections for the Treatment of Schizophrenia", the second-generation antipsychotic long-acting injections are used as the first-line treatment strategy for patients with schizophrenia in the acute and maintenance phases. Professor Cai Jun, chief physician of the Mental Health Center affiliated to Shanghai Jiaotong University School of Medicine, pointed out: “Based on the characteristics of high recurrence of schizophrenia, we advocate the early use of long-acting injections at all stages of the disease course.
As the first independent research and development in my country, The second-generation antipsychotic long-acting injection, Rexinto® is further improved and upgraded on the basis of the existing commercially available long-acting injections.
It is suitable for the whole course of treatment of schizophrenia and provides patients with new treatment options.
"Innovative microsphere preparation to further improve the safety and compliance of schizophrenia treatmentIn recent years, the main treatment for schizophrenia has been drug therapy, usually combined with psychotherapy and social support.
Currently, alternative antipsychotic medications include oral medications or long-acting injections.
However, because oral drugs need to be taken on time and in the amount every day, some patients often cause fluctuations in their condition due to their own or objective factors, and a number of studies have shown that long-acting injections are more effective in reducing treatment interruption caused by treatment interruptions than oral dosage forms.
The probability of recurrence and re-hospitalization, improve patient compliance with treatment, prevent recurrence, and have higher safety.
Rexinto® is injected intramuscularly once every two weeks, which can significantly improve the compliance of oral antipsychotics, which is common in patients with schizophrenia.
Compared with oral preparations, the frequency of administration of Rexinto® is significantly reduced, which can effectively improve patients' missed or forgotten medication.
In addition, the blood concentration of Rexinto® in the body is stable, which reduces the difference between peaks and troughs of blood concentration compared with oral preparations, helps reduce the risk of dose-dependent side effects, and improves the safety of patients' medication.
“，、、。，、，、。”。
“，、、。，、，、。”。
®，，。，、、，。，、。
，®。202111240，®。，，®，，。“®，，；01，，。” 。®，，，：（LY03003）、、（LY01005）、、 LY03009。®，，。
®，，。，、、，。，、。
，®。202111240，®。，，®，，。“®，，；01，，。” 。®，，，：（LY03003）、、（LY01005）、、 LY03009。®，，。
According to the latest Global Burden of Disease (GBD) report, approximately 21 million people worldwide suffer from schizophrenia, and the number of illnesses is on the rise.
Most of these patients live in low- and middle-income countries, and there are obvious treatments for schizophrenia in these countries.
insufficient.On March 27, Luye Pharmaceutical Group announced that my country's first self-developed new anti-schizophrenia drug-Rexinto® (Risperidone Microspheres for Injection (II)) was officially launched in China.
Rexinto® is a sustained-release microsphere preparation for injection.
It is injected intramuscularly once every two weeks.
It is used to treat acute and chronic schizophrenia and other various psychotic states with obvious positive and negative symptoms, which can reduce the Affective symptoms related to schizophrenia.Recinto® is developed based on Luye Pharma’s world-leading microsphere technology platform.
As China’s first innovative microsphere preparation with independent intellectual property rights and global registration, it is also the first self-developed second-generation long-acting injection of an antipsychotic drug in my country.
The drug’s launch is not only for about 10 million people with schizophrenia in China.
The patient's return to society brings new hope, and it also means that Luye Pharma's innovative microsphere technology research and development platform, which has been deeply cultivated for many years, has successfully achieved industrialization and demonstrated its global leadership.Many guidelines at home and abroad strongly recommend that long-acting injections are the first choice for improving patient compliance and recurrenceSchizophrenia is one of a group of common mental diseases that seriously impairs patients' living ability and social function.
The main difficulty in the treatment of schizophrenia is the recurrence of the disease caused by the patient's interruption of treatment or self-reduction of medication.
According to the data, 60% of patients with the first attack have poor medication compliance, and the recurrence rate within 5 years exceeds 80%.
Multiple recurrences lead to prolonged course of the disease, increase the difficulty of treatment, and greatly increase the cost of treatment.
Professor Cai Jun, Chief Physician of the Mental Health Center Affiliated to Shanghai Jiaotong University School of Medicine
Although there are more and more antipsychotic drugs available, they still fail to fully meet the clinical needs.
Poor compliance and high recurrence are still the main problems and challenges in the treatment of schizophrenia.
"The treatment concept of schizophrenia has changed from controlling symptoms to improving cognition, promoting recovery, and finally returning patients to society.
In this process, improving patient compliance to prevent recurrence is the key to the treatment of schizophrenia.
" Shanghai Jiaotong Professor Cai Jun, chief physician of the Mental Health Center affiliated to the University School of Medicine, said: “Long-acting antipsychotics can significantly improve patient compliance compared with oral preparations, and are an important treatment strategy to prevent recurrence.
”
Poor compliance and high recurrence are still the main problems and challenges in the treatment of schizophrenia.
"The treatment concept of schizophrenia has changed from controlling symptoms to improving cognition, promoting recovery, and finally returning patients to society.
In this process, improving patient compliance to prevent recurrence is the key to the treatment of schizophrenia.
" Shanghai Jiaotong Professor Cai Jun, chief physician of the Mental Health Center affiliated to the University School of Medicine, said: “Long-acting antipsychotics can significantly improve patient compliance compared with oral preparations, and are an important treatment strategy to prevent recurrence.
”
From the perspective of global treatment concepts and trends, the use of long-acting preparations is one of the main methods for the treatment of schizophrenia.
Recommended by a number of domestic and foreign guidelines, long-acting preparations range from providing compliance & preventing recurrence to all stages of the entire disease course.
The 2014 APA guidelines recommend that long-acting preparations are recommended for patients who have relapsed due to poor compliance.
The 2011 BAP guidelines recommended that patients prefer to use long-acting preparations.
Patients with poor compliance or compliance issues and patients who relapse due to compliance are recommended to use long-acting preparations.
The 2017 CPA guidelines recommend that the use of long-acting preparations should be recommended when discussing the existence and use of long-acting preparations with patients and their families at all stages of the disease, including the critical period of 2-5 years.
In addition, in my country's "Expert Consensus on Long-acting Antipsychotic Injections for the Treatment of Schizophrenia", the second-generation antipsychotic long-acting injections are used as the first-line treatment strategy for patients with schizophrenia in the acute and maintenance phases. Professor Cai Jun, chief physician of the Mental Health Center affiliated to Shanghai Jiaotong University School of Medicine, pointed out: “Based on the characteristics of high recurrence of schizophrenia, we advocate the early use of long-acting injections at all stages of the disease course.
As the first independent research and development in my country, The second-generation antipsychotic long-acting injection, Rexinto® is further improved and upgraded on the basis of the existing commercially available long-acting injections.
It is suitable for the whole course of treatment of schizophrenia and provides patients with new treatment options.
"Innovative microsphere preparation to further improve the safety and compliance of schizophrenia treatmentIn recent years, the main treatment for schizophrenia has been drug therapy, usually combined with psychotherapy and social support.
Currently, alternative antipsychotic medications include oral medications or long-acting injections.
However, because oral drugs need to be taken on time and in the amount every day, some patients often cause fluctuations in their condition due to their own or objective factors, and a number of studies have shown that long-acting injections are more effective in reducing treatment interruption caused by treatment interruptions than oral dosage forms.
The probability of recurrence and re-hospitalization, improve patient compliance with treatment, prevent recurrence, and have higher safety.
Rexinto® is injected intramuscularly once every two weeks, which can significantly improve the compliance of oral antipsychotics, which is common in patients with schizophrenia.
Compared with oral preparations, the frequency of administration of Rexinto® is significantly reduced, which can effectively improve patients' missed or forgotten medication.
In addition, the blood concentration of Rexinto® in the body is stable, which reduces the difference between peaks and troughs of blood concentration compared with oral preparations, helps reduce the risk of dose-dependent side effects, and improves the safety of patients' medication.
Professor Mei Qiyi, Chief Physician of Suzhou Guangji Hospital
"Most patients with schizophrenia have difficulty in taking oral medications every day.
Part of the reason is that they stop taking medications because they cannot tolerate the adverse effects of the medications.
This is also the reason for poor medication compliance.
Recinto® administration method and stable and long-lasting blood medication The concentration can better guarantee the long-term effective medication of patients.
" Professor Mei Qiyi, chief physician of Suzhou Guangji Hospital pointed out. "Rexinto® takes effect quickly after injection.
There is no need to supplement oral preparations after the first injection of Rexinto®, and it can reach steady-state blood drug concentration faster than other drugs, and can quickly control the patient’s psychotic symptoms.
The rapid removal after stopping the drug is more conducive to the rapid adjustment of the treatment plan by the doctor according to the condition.
" Professor Mei Qiyi added: "It is great to see China's preparation innovation in the field of schizophrenia treatment, providing patients with new drugs with more clinical advantages.
I believe that with the launch of Recinto®, it can bring good news to more patients' prognosis improvement and return to society.
"It is reported that Rexinto® has obvious therapeutic advantages.
Rexinto® was included in the priority review procedure by the Drug Evaluation Center of the National Medical Products Administration in December 2019, and received the National Drug Supervision on January 12, 2021.
Authority’s listing approval.
In addition to being approved for listing in China, Rexinto®'s global registration and application work is also being carried out simultaneously.
Currently, it has entered the new drug marketing application stage in the United States and is conducting key clinical studies in Europe. Build the world's leading microsphere technology platform to continuously improve the clinical benefits of patients
"The purpose of formulation innovation is to solve unmet clinical needs, covering various aspects such as efficacy, compliance, and side effects.
We pay attention to the experience and needs of patients, and are committed to providing differentiated and innovative products with clinical value to relieve patients.
We make unremitting efforts to improve the burden of disease and improve the clinical benefits of patients.
” said Mr.
Yang Rongbing, President of Luye Pharmaceutical Group.
The listing of Recinto® means that Luye Pharma has successfully broken the long-term monopoly of overseas technology and has become one of the few domestic companies that have mastered the key technology of microsphere preparations.
After more than ten years of unremitting efforts, Luye Pharma has established core key technologies including high drug loading and low burst release microsphere preparation technology, long-acting sustained-release preparations in vivo and in vitro release correlation evaluation, microsphere industrialized preparation technology and equipment, etc.
The construction of the platform has formed an international competitiveness in this field.
In particular, the industrialization research level of its microsphere technology platform has been in a leading position in the world, and the technical equipment and preparation process of the pilot test are all self-developed.
After breakthroughs in the R&D and industrialization of the microsphere technology platform, the commercialization process of the first microsphere product, Recinto®, is also accelerating.
Only more than 40 days after it was approved for marketing on January 12, 2021, Recinto® has begun to supply medicines to many provinces and cities across the country.
In addition, in order to benefit more patients from around the world, Rexinto®'s global registration and application work is also being carried out simultaneously.
Currently, it has entered the new drug market application stage in the United States and is conducting key clinical studies in Europe. "The listing of Rexinto® is of great significance.
It confirms our long-term commitment to provide innovative treatment solutions around the needs of patients; it is also our microsphere technology platform to achieve breakthrough results from 0 to 1 , To promote the platform to accelerate the launch of more innovative microsphere preparations and serve more patients,” said Mr.
Yang Rongbing.
In addition to Recinto®, which is already on the market, Luye Pharma’s innovative microsphere platform will continue to leverage its core technological advantages and have a deep layout in the field of major diseases such as tumors and central nervous system.
A series of microsphere products in different stages of development include: treatment of Parkinson’s Rotigotine sustained-release microspheres for injection (LY03003) for the treatment of disease, goserelin acetate sustained-release microspheres for injection (LY01005) for the treatment of prostate cancer, breast cancer and other sex hormone-dependent diseases, treatment of Parkinson’s disease, restlessness High-quality innovative drugs such as LY03009 for leg syndrome.
Subsequent new drugs will form a rich product portfolio with Recinto®, leverage the company's superior strength in this technical field, and bring new high-quality treatment options to patients.
Part of the reason is that they stop taking medications because they cannot tolerate the adverse effects of the medications.
This is also the reason for poor medication compliance.
Recinto® administration method and stable and long-lasting blood medication The concentration can better guarantee the long-term effective medication of patients.
" Professor Mei Qiyi, chief physician of Suzhou Guangji Hospital pointed out. "Rexinto® takes effect quickly after injection.
There is no need to supplement oral preparations after the first injection of Rexinto®, and it can reach steady-state blood drug concentration faster than other drugs, and can quickly control the patient’s psychotic symptoms.
The rapid removal after stopping the drug is more conducive to the rapid adjustment of the treatment plan by the doctor according to the condition.
" Professor Mei Qiyi added: "It is great to see China's preparation innovation in the field of schizophrenia treatment, providing patients with new drugs with more clinical advantages.
I believe that with the launch of Recinto®, it can bring good news to more patients' prognosis improvement and return to society.
"It is reported that Rexinto® has obvious therapeutic advantages.
Rexinto® was included in the priority review procedure by the Drug Evaluation Center of the National Medical Products Administration in December 2019, and received the National Drug Supervision on January 12, 2021.
Authority’s listing approval.
In addition to being approved for listing in China, Rexinto®'s global registration and application work is also being carried out simultaneously.
Currently, it has entered the new drug marketing application stage in the United States and is conducting key clinical studies in Europe. Build the world's leading microsphere technology platform to continuously improve the clinical benefits of patients
"The purpose of formulation innovation is to solve unmet clinical needs, covering various aspects such as efficacy, compliance, and side effects.
We pay attention to the experience and needs of patients, and are committed to providing differentiated and innovative products with clinical value to relieve patients.
We make unremitting efforts to improve the burden of disease and improve the clinical benefits of patients.
” said Mr.
Yang Rongbing, President of Luye Pharmaceutical Group.
Mr.
Yang Rongbing, President of Luye Pharmaceutical Group
Yang Rongbing, President of Luye Pharmaceutical Group
As one of the representatives of new high-end preparations, microsphere preparations are designed for the release speed and cycle according to clinical needs, and can continuously release the drug for a week to several months, and achieve the purpose of stable release of the drug, improved efficacy, and reduced side effects.
As a complex preparation, the development and production of microsphere preparations are difficult, and technical barriers are high.
This technology is mainly mastered by several foreign companies.
As a complex preparation, the development and production of microsphere preparations are difficult, and technical barriers are high.
This technology is mainly mastered by several foreign companies.
The listing of Recinto® means that Luye Pharma has successfully broken the long-term monopoly of overseas technology and has become one of the few domestic companies that have mastered the key technology of microsphere preparations.
After more than ten years of unremitting efforts, Luye Pharma has established core key technologies including high drug loading and low burst release microsphere preparation technology, long-acting sustained-release preparations in vivo and in vitro release correlation evaluation, microsphere industrialized preparation technology and equipment, etc.
The construction of the platform has formed an international competitiveness in this field.
In particular, the industrialization research level of its microsphere technology platform has been in a leading position in the world, and the technical equipment and preparation process of the pilot test are all self-developed.
After breakthroughs in the R&D and industrialization of the microsphere technology platform, the commercialization process of the first microsphere product, Recinto®, is also accelerating.
Only more than 40 days after it was approved for marketing on January 12, 2021, Recinto® has begun to supply medicines to many provinces and cities across the country.
In addition, in order to benefit more patients from around the world, Rexinto®'s global registration and application work is also being carried out simultaneously.
Currently, it has entered the new drug market application stage in the United States and is conducting key clinical studies in Europe. "The listing of Rexinto® is of great significance.
It confirms our long-term commitment to provide innovative treatment solutions around the needs of patients; it is also our microsphere technology platform to achieve breakthrough results from 0 to 1 , To promote the platform to accelerate the launch of more innovative microsphere preparations and serve more patients,” said Mr.
Yang Rongbing.
In addition to Recinto®, which is already on the market, Luye Pharma’s innovative microsphere platform will continue to leverage its core technological advantages and have a deep layout in the field of major diseases such as tumors and central nervous system.
A series of microsphere products in different stages of development include: treatment of Parkinson’s Rotigotine sustained-release microspheres for injection (LY03003) for the treatment of disease, goserelin acetate sustained-release microspheres for injection (LY01005) for the treatment of prostate cancer, breast cancer and other sex hormone-dependent diseases, treatment of Parkinson’s disease, restlessness High-quality innovative drugs such as LY03009 for leg syndrome.
Subsequent new drugs will form a rich product portfolio with Recinto®, leverage the company's superior strength in this technical field, and bring new high-quality treatment options to patients.
Professor Cai Jun, Chief Physician of the Mental Health Center Affiliated to Shanghai Jiaotong University School of Medicine
Although there are more and more antipsychotic drugs available, they still fail to fully meet the clinical needs.
Poor compliance and high recurrence are still the main problems and challenges in the treatment of schizophrenia.
"The treatment concept of schizophrenia has changed from controlling symptoms to improving cognition, promoting recovery, and finally returning patients to society.
In this process, improving patient compliance to prevent recurrence is the key to the treatment of schizophrenia.
" Shanghai Jiaotong Professor Cai Jun, chief physician of the Mental Health Center affiliated to the University School of Medicine, said: “Long-acting antipsychotics can significantly improve patient compliance compared with oral preparations, and are an important treatment strategy to prevent recurrence.
”
Although there are more and more antipsychotic drugs available, they still fail to fully meet the clinical needs. Poor compliance and high recurrence are still the main problems and challenges in the treatment of schizophrenia.
"The treatment concept of schizophrenia has changed from controlling symptoms to improving cognition, promoting recovery, and finally returning patients to society.
In this process, improving patient compliance to prevent recurrence is the key to the treatment of schizophrenia.
" Shanghai Jiaotong Professor Cai Jun, chief physician of the Mental Health Center affiliated to the University School of Medicine, said: “Long-acting antipsychotics can significantly improve patient compliance compared with oral preparations, and are an important treatment strategy to prevent recurrence.
”
Poor compliance and high recurrence are still the main problems and challenges in the treatment of schizophrenia.
"The treatment concept of schizophrenia has changed from controlling symptoms to improving cognition, promoting recovery, and finally returning patients to society.
In this process, improving patient compliance to prevent recurrence is the key to the treatment of schizophrenia.
" Shanghai Jiaotong Professor Cai Jun, chief physician of the Mental Health Center affiliated to the University School of Medicine, said: “Long-acting antipsychotics can significantly improve patient compliance compared with oral preparations, and are an important treatment strategy to prevent recurrence.
”
From the perspective of global treatment concepts and trends, the use of long-acting preparations is one of the main methods for the treatment of schizophrenia.
Recommended by a number of domestic and foreign guidelines, long-acting preparations range from providing compliance & preventing recurrence to all stages of the entire disease course.
The 2014 APA guidelines recommend that long-acting preparations are recommended for patients who have relapsed due to poor compliance.
The 2011 BAP guidelines recommended that patients prefer to use long-acting preparations.
Patients with poor compliance or compliance issues and patients who relapse due to compliance are recommended to use long-acting preparations.
The 2017 CPA guidelines recommend that the use of long-acting preparations should be recommended when discussing the existence and use of long-acting preparations with patients and their families at all stages of the disease, including the critical period of 2-5 years.
In addition, in my country's "Expert Consensus on Long-acting Antipsychotic Injections for the Treatment of Schizophrenia", the second-generation antipsychotic long-acting injections are used as the first-line treatment strategy for patients with schizophrenia in the acute and maintenance phases. Professor Cai Jun, chief physician of the Mental Health Center affiliated to Shanghai Jiaotong University School of Medicine, pointed out: “Based on the characteristics of high recurrence of schizophrenia, we advocate the early use of long-acting injections at all stages of the disease course.
As the first independent research and development in my country, The second-generation antipsychotic long-acting injection, Rexinto® is further improved and upgraded on the basis of the existing commercially available long-acting injections.
It is suitable for the whole course of treatment of schizophrenia and provides patients with new treatment options.
"Innovative microsphere preparation to further improve the safety and compliance of schizophrenia treatmentIn recent years, the main treatment for schizophrenia has been drug therapy, usually combined with psychotherapy and social support.
Currently, alternative antipsychotic medications include oral medications or long-acting injections.
However, because oral drugs need to be taken on time and in the amount every day, some patients often cause fluctuations in their condition due to their own or objective factors, and a number of studies have shown that long-acting injections are more effective in reducing treatment interruption caused by treatment interruptions than oral dosage forms.
The probability of recurrence and re-hospitalization, improve patient compliance with treatment, prevent recurrence, and have higher safety.
Rexinto® is injected intramuscularly once every two weeks, which can significantly improve the compliance of oral antipsychotics, which is common in patients with schizophrenia.
Compared with oral preparations, the frequency of administration of Rexinto® is significantly reduced, which can effectively improve patients' missed or forgotten medication.
In addition, the blood concentration of Rexinto® in the body is stable, which reduces the difference between peaks and troughs of blood concentration compared with oral preparations, helps reduce the risk of dose-dependent side effects, and improves the safety of patients' medication.
Professor Mei Qiyi, Chief Physician of Suzhou Guangji Hospital
"Most patients with schizophrenia have difficulty in taking oral medications every day.
Part of the reason is that they stop taking medications because they cannot tolerate the adverse effects of the medications.
This is also the reason for poor medication compliance.
Recinto® administration method and stable and long-lasting blood medication The concentration can better guarantee the long-term effective medication of patients.
" Professor Mei Qiyi, chief physician of Suzhou Guangji Hospital pointed out. "Rexinto® takes effect quickly after injection.
There is no need to supplement oral preparations after the first injection of Rexinto®, and it can reach steady-state blood drug concentration faster than other drugs, and can quickly control the patient’s psychotic symptoms.
The rapid removal after stopping the drug is more conducive to the rapid adjustment of the treatment plan by the doctor according to the condition.
" Professor Mei Qiyi added: "It is great to see China's preparation innovation in the field of schizophrenia treatment, providing patients with new drugs with more clinical advantages.
I believe that with the launch of Recinto®, it can bring good news to more patients' prognosis improvement and return to society.
"It is reported that Rexinto® has obvious therapeutic advantages.
Rexinto® was included in the priority review procedure by the Drug Evaluation Center of the National Medical Products Administration in December 2019, and received the National Drug Supervision on January 12, 2021.
Authority’s listing approval.
In addition to being approved for listing in China, Rexinto®'s global registration and application work is also being carried out simultaneously.
Currently, it has entered the new drug marketing application stage in the United States and is conducting key clinical studies in Europe. Build the world's leading microsphere technology platform to continuously improve the clinical benefits of patients
"The purpose of formulation innovation is to solve unmet clinical needs, covering various aspects such as efficacy, compliance, and side effects.
We pay attention to the experience and needs of patients, and are committed to providing differentiated and innovative products with clinical value to relieve patients.
We make unremitting efforts to improve the burden of disease and improve the clinical benefits of patients.
” said Mr.
Yang Rongbing, President of Luye Pharmaceutical Group.
The listing of Recinto® means that Luye Pharma has successfully broken the long-term monopoly of overseas technology and has become one of the few domestic companies that have mastered the key technology of microsphere preparations.
After more than ten years of unremitting efforts, Luye Pharma has established core key technologies including high drug loading and low burst release microsphere preparation technology, long-acting sustained-release preparations in vivo and in vitro release correlation evaluation, microsphere industrialized preparation technology and equipment, etc.
The construction of the platform has formed an international competitiveness in this field.
In particular, the industrialization research level of its microsphere technology platform has been in a leading position in the world, and the technical equipment and preparation process of the pilot test are all self-developed.
After breakthroughs in the R&D and industrialization of the microsphere technology platform, the commercialization process of the first microsphere product, Recinto®, is also accelerating.
Only more than 40 days after it was approved for marketing on January 12, 2021, Recinto® has begun to supply medicines to many provinces and cities across the country.
In addition, in order to benefit more patients from around the world, Rexinto®'s global registration and application work is also being carried out simultaneously.
Currently, it has entered the new drug market application stage in the United States and is conducting key clinical studies in Europe. "The listing of Rexinto® is of great significance.
It confirms our long-term commitment to provide innovative treatment solutions around the needs of patients; it is also our microsphere technology platform to achieve breakthrough results from 0 to 1 , To promote the platform to accelerate the launch of more innovative microsphere preparations and serve more patients,” said Mr.
Yang Rongbing.
In addition to Recinto®, which is already on the market, Luye Pharma’s innovative microsphere platform will continue to leverage its core technological advantages and have a deep layout in the field of major diseases such as tumors and central nervous system.
A series of microsphere products in different stages of development include: treatment of Parkinson’s Rotigotine sustained-release microspheres for injection (LY03003) for the treatment of disease, goserelin acetate sustained-release microspheres for injection (LY01005) for the treatment of prostate cancer, breast cancer and other sex hormone-dependent diseases, treatment of Parkinson’s disease, restlessness High-quality innovative drugs such as LY03009 for leg syndrome.
Subsequent new drugs will form a rich product portfolio with Recinto®, leverage the company's superior strength in this technical field, and bring new high-quality treatment options to patients.
Part of the reason is that they stop taking medications because they cannot tolerate the adverse effects of the medications.
This is also the reason for poor medication compliance.
Recinto® administration method and stable and long-lasting blood medication The concentration can better guarantee the long-term effective medication of patients.
" Professor Mei Qiyi, chief physician of Suzhou Guangji Hospital pointed out. "Rexinto® takes effect quickly after injection.
There is no need to supplement oral preparations after the first injection of Rexinto®, and it can reach steady-state blood drug concentration faster than other drugs, and can quickly control the patient’s psychotic symptoms.
The rapid removal after stopping the drug is more conducive to the rapid adjustment of the treatment plan by the doctor according to the condition.
" Professor Mei Qiyi added: "It is great to see China's preparation innovation in the field of schizophrenia treatment, providing patients with new drugs with more clinical advantages.
I believe that with the launch of Recinto®, it can bring good news to more patients' prognosis improvement and return to society.
"It is reported that Rexinto® has obvious therapeutic advantages.
Rexinto® was included in the priority review procedure by the Drug Evaluation Center of the National Medical Products Administration in December 2019, and received the National Drug Supervision on January 12, 2021.
Authority’s listing approval.
In addition to being approved for listing in China, Rexinto®'s global registration and application work is also being carried out simultaneously.
Currently, it has entered the new drug marketing application stage in the United States and is conducting key clinical studies in Europe. Build the world's leading microsphere technology platform to continuously improve the clinical benefits of patients
"The purpose of formulation innovation is to solve unmet clinical needs, covering various aspects such as efficacy, compliance, and side effects.
We pay attention to the experience and needs of patients, and are committed to providing differentiated and innovative products with clinical value to relieve patients.
We make unremitting efforts to improve the burden of disease and improve the clinical benefits of patients.
” said Mr.
Yang Rongbing, President of Luye Pharmaceutical Group.
Mr.
Yang Rongbing, President of Luye Pharmaceutical Group
Yang Rongbing, President of Luye Pharmaceutical Group
As one of the representatives of new high-end preparations, microsphere preparations are designed for the release speed and cycle according to clinical needs, and can continuously release the drug for a week to several months, and achieve the purpose of stable release of the drug, improved efficacy, and reduced side effects.
As a complex preparation, the development and production of microsphere preparations are difficult, and technical barriers are high.
This technology is mainly mastered by several foreign companies.
As a complex preparation, the development and production of microsphere preparations are difficult, and technical barriers are high.
This technology is mainly mastered by several foreign companies.
The listing of Recinto® means that Luye Pharma has successfully broken the long-term monopoly of overseas technology and has become one of the few domestic companies that have mastered the key technology of microsphere preparations.
After more than ten years of unremitting efforts, Luye Pharma has established core key technologies including high drug loading and low burst release microsphere preparation technology, long-acting sustained-release preparations in vivo and in vitro release correlation evaluation, microsphere industrialized preparation technology and equipment, etc.
The construction of the platform has formed an international competitiveness in this field.
In particular, the industrialization research level of its microsphere technology platform has been in a leading position in the world, and the technical equipment and preparation process of the pilot test are all self-developed.
After breakthroughs in the R&D and industrialization of the microsphere technology platform, the commercialization process of the first microsphere product, Recinto®, is also accelerating.
Only more than 40 days after it was approved for marketing on January 12, 2021, Recinto® has begun to supply medicines to many provinces and cities across the country.
In addition, in order to benefit more patients from around the world, Rexinto®'s global registration and application work is also being carried out simultaneously.
Currently, it has entered the new drug market application stage in the United States and is conducting key clinical studies in Europe. "The listing of Rexinto® is of great significance.
It confirms our long-term commitment to provide innovative treatment solutions around the needs of patients; it is also our microsphere technology platform to achieve breakthrough results from 0 to 1 , To promote the platform to accelerate the launch of more innovative microsphere preparations and serve more patients,” said Mr.
Yang Rongbing.
In addition to Recinto®, which is already on the market, Luye Pharma’s innovative microsphere platform will continue to leverage its core technological advantages and have a deep layout in the field of major diseases such as tumors and central nervous system.
A series of microsphere products in different stages of development include: treatment of Parkinson’s Rotigotine sustained-release microspheres for injection (LY03003) for the treatment of disease, goserelin acetate sustained-release microspheres for injection (LY01005) for the treatment of prostate cancer, breast cancer and other sex hormone-dependent diseases, treatment of Parkinson’s disease, restlessness High-quality innovative drugs such as LY03009 for leg syndrome.
Subsequent new drugs will form a rich product portfolio with Recinto®, leverage the company's superior strength in this technical field, and bring new high-quality treatment options to patients.
From the perspective of global treatment concepts and trends, the use of long-acting preparations is one of the main methods for the treatment of schizophrenia.
Recommended by a number of domestic and foreign guidelines, long-acting preparations range from providing compliance & preventing recurrence to all stages of the entire disease course.
The 2014 APA guidelines recommend that long-acting preparations are recommended for patients who have relapsed due to poor compliance.
The 2011 BAP guidelines recommended that patients prefer to use long-acting preparations.
Patients with poor compliance or compliance issues and patients who relapse due to compliance are recommended to use long-acting preparations.
The 2017 CPA guidelines recommend that the use of long-acting preparations should be recommended when discussing the existence and use of long-acting preparations with patients and their families at all stages of the disease, including the critical period of 2-5 years.
In addition, in my country's "Expert Consensus on Long-acting Antipsychotic Injections for the Treatment of Schizophrenia", the second-generation antipsychotic long-acting injections are used as the first-line treatment strategy for patients with schizophrenia in the acute and maintenance phases. Professor Cai Jun, chief physician of the Mental Health Center affiliated to Shanghai Jiaotong University School of Medicine, pointed out: “Based on the characteristics of high recurrence of schizophrenia, we advocate the early use of long-acting injections at all stages of the disease course.
As the first independent research and development in my country, The second-generation antipsychotic long-acting injection, Rexinto® is further improved and upgraded on the basis of the existing commercially available long-acting injections.
It is suitable for the whole course of treatment of schizophrenia and provides patients with new treatment options.
"Innovative microsphere preparation to further improve the safety and compliance of schizophrenia treatmentIn recent years, the main treatment for schizophrenia has been drug therapy, usually combined with psychotherapy and social support.
Currently, alternative antipsychotic medications include oral medications or long-acting injections.
However, because oral drugs need to be taken on time and in the amount every day, some patients often cause fluctuations in their condition due to their own or objective factors, and a number of studies have shown that long-acting injections are more effective in reducing treatment interruption caused by treatment interruptions than oral dosage forms.
The probability of recurrence and re-hospitalization, improve patient compliance with treatment, prevent recurrence, and have higher safety.
Rexinto® is injected intramuscularly once every two weeks, which can significantly improve the compliance of oral antipsychotics, which is common in patients with schizophrenia.
Compared with oral preparations, the frequency of administration of Rexinto® is significantly reduced, which can effectively improve patients' missed or forgotten medication.
In addition, the blood concentration of Rexinto® in the body is stable, which reduces the difference between peaks and troughs of blood concentration compared with oral preparations, helps reduce the risk of dose-dependent side effects, and improves the safety of patients' medication.
From the perspective of global treatment concepts and trends, the use of long-acting preparations is one of the main methods for the treatment of schizophrenia.
Recommended by a number of domestic and foreign guidelines, long-acting preparations range from providing compliance & preventing recurrence to all stages of the entire disease course.
The 2014 APA guidelines recommend that long-acting preparations are recommended for patients who have relapsed due to poor compliance.
The 2011 BAP guidelines recommended that patients prefer to use long-acting preparations.
Patients with poor compliance or compliance issues and patients who relapse due to compliance are recommended to use long-acting preparations.
The 2017 CPA guidelines recommend that the use of long-acting preparations should be recommended when discussing the existence and use of long-acting preparations with patients and their families at all stages of the disease, including the critical period of 2-5 years.
In addition, in my country's "Expert Consensus on Long-acting Antipsychotic Injections for the Treatment of Schizophrenia", the second-generation antipsychotic long-acting injections are used as the first-line treatment strategy for patients with schizophrenia in the acute and maintenance phases.
From the perspective of global treatment concepts and trends, the use of long-acting preparations is one of the main methods for the treatment of schizophrenia.
Recommended by a number of domestic and foreign guidelines, long-acting preparations range from providing compliance & preventing recurrence to all stages of the entire disease course.
The 2014 APA guidelines recommend that long-acting preparations are recommended for patients who have relapsed due to poor compliance.
The 2011 BAP guidelines recommended that patients prefer to use long-acting preparations.
Patients with poor compliance or compliance issues and patients who relapse due to compliance are recommended to use long-acting preparations.
The 2017 CPA guidelines recommend that the use of long-acting preparations should be recommended when discussing the existence and use of long-acting preparations with patients and their families at all stages of the disease, including the critical period of 2-5 years.
In addition, in my country's "Expert Consensus on Long-acting Antipsychotic Injections for the Treatment of Schizophrenia", the second-generation antipsychotic long-acting injections are used as the first-line treatment strategy for patients with schizophrenia in the acute and maintenance phases.
From the perspective of global treatment concepts and trends, the use of long-acting preparations is one of the main methods for the treatment of schizophrenia.
Recommended by a number of domestic and foreign guidelines, long-acting preparations range from providing compliance & preventing recurrence to all stages of the entire disease course.
The 2014 APA guidelines recommend that long-acting preparations are recommended for patients who have relapsed due to poor compliance.
The 2011 BAP guidelines recommended that patients prefer to use long-acting preparations.
Patients with poor compliance or compliance issues and patients who relapse due to compliance are recommended to use long-acting preparations.
The 2017 CPA guidelines recommend that the use of long-acting preparations should be recommended when discussing the existence and use of long-acting preparations with patients and their families at all stages of the disease, including the critical period of 2-5 years.
In addition, in my country's "Expert Consensus on Long-acting Antipsychotic Injections for the Treatment of Schizophrenia", the second-generation antipsychotic long-acting injections are used as the first-line treatment strategy for patients with schizophrenia in the acute and maintenance phases. Professor Cai Jun, chief physician of the Mental Health Center affiliated to Shanghai Jiaotong University School of Medicine, pointed out: “Based on the characteristics of high recurrence of schizophrenia, we advocate the early use of long-acting injections at all stages of the disease course.
As the first independent research and development in my country, The second-generation antipsychotic long-acting injection, Rexinto® is further improved and upgraded on the basis of the existing commercially available long-acting injections.
It is suitable for the whole course of treatment of schizophrenia and provides patients with new treatment options.
"Innovative microsphere preparation to further improve the safety and compliance of schizophrenia treatmentIn recent years, the main treatment for schizophrenia has been drug therapy, usually combined with psychotherapy and social support.
Currently, alternative antipsychotic medications include oral medications or long-acting injections.
However, because oral drugs need to be taken on time and in the amount every day, some patients often cause fluctuations in their condition due to their own or objective factors, and a number of studies have shown that long-acting injections are more effective in reducing treatment interruption caused by treatment interruptions than oral dosage forms.
The probability of recurrence and re-hospitalization, improve patient compliance with treatment, prevent recurrence, and have higher safety.
Rexinto® is injected intramuscularly once every two weeks, which can significantly improve the compliance of oral antipsychotics, which is common in patients with schizophrenia.
Compared with oral preparations, the frequency of administration of Rexinto® is significantly reduced, which can effectively improve patients' missed or forgotten medication.
In addition, the blood concentration of Rexinto® in the body is stable, which reduces the difference between peaks and troughs of blood concentration compared with oral preparations, helps reduce the risk of dose-dependent side effects, and improves the safety of patients' medication.
Professor Mei Qiyi, Chief Physician of Suzhou Guangji Hospital
Professor Mei Qiyi, Chief Physician of Suzhou Guangji Hospital"Most patients with schizophrenia have difficulty in taking oral medications every day.
Part of the reason is that they stop taking medications because they cannot tolerate the adverse effects of the medications.
This is also the reason for poor medication compliance.
Recinto® administration method and stable and long-lasting blood medication The concentration can better guarantee the long-term effective medication of patients.
" Professor Mei Qiyi, chief physician of Suzhou Guangji Hospital pointed out.
"Rexinto® takes effect quickly after injection.
There is no need to supplement oral preparations after the first injection of Rexinto®, and it can reach steady-state blood drug concentration faster than other drugs, and can quickly control the patient’s psychotic symptoms.
The rapid removal after stopping the drug is more conducive to the rapid adjustment of the treatment plan by the doctor according to the condition.
" Professor Mei Qiyi added: "It is great to see China's preparation innovation in the field of schizophrenia treatment, providing patients with new drugs with more clinical advantages.
I believe that with the launch of Recinto®, it can bring good news to more patients' prognosis improvement and return to society.
"It is reported that Rexinto® has obvious therapeutic advantages.
Rexinto® was included in the priority review procedure by the Drug Evaluation Center of the National Medical Products Administration in December 2019, and received the National Drug Supervision on January 12, 2021.
Authority’s listing approval.
In addition to being approved for listing in China, Rexinto®'s global registration and application work is also being carried out simultaneously.
Currently, it has entered the new drug marketing application stage in the United States and is conducting key clinical studies in Europe. Build the world's leading microsphere technology platform to continuously improve the clinical benefits of patients
"The purpose of formulation innovation is to solve unmet clinical needs, covering various aspects such as efficacy, compliance, and side effects.
We pay attention to the experience and needs of patients, and are committed to providing differentiated and innovative products with clinical value to relieve patients.
We make unremitting efforts to improve the burden of disease and improve the clinical benefits of patients.
” said Mr.
Yang Rongbing, President of Luye Pharmaceutical Group.
®，，。，、、，。，、。
，®。202111240，®。，，®，，。“®，，；01，，。” 。®，，，：（LY03003）、、（LY01005）、、 LY03009。®，，。
“，，。®。”。“®，®，，，，。”：“，。®，、。”，®，®201912，2021112。，®，，。，Part of the reason is that they stop taking medications because they cannot tolerate the adverse effects of the medications.
This is also the reason for poor medication compliance.
Recinto® administration method and stable and long-lasting blood medication The concentration can better guarantee the long-term effective medication of patients.
" Professor Mei Qiyi, chief physician of Suzhou Guangji Hospital pointed out.
"Rexinto® takes effect quickly after injection.
There is no need to supplement oral preparations after the first injection of Rexinto®, and it can reach steady-state blood drug concentration faster than other drugs, and can quickly control the patient’s psychotic symptoms.
The rapid removal after stopping the drug is more conducive to the rapid adjustment of the treatment plan by the doctor according to the condition.
" Professor Mei Qiyi added: "It is great to see China's preparation innovation in the field of schizophrenia treatment, providing patients with new drugs with more clinical advantages.
I believe that with the launch of Recinto®, it can bring good news to more patients' prognosis improvement and return to society.
"It is reported that Rexinto® has obvious therapeutic advantages.
Rexinto® was included in the priority review procedure by the Drug Evaluation Center of the National Medical Products Administration in December 2019, and received the National Drug Supervision on January 12, 2021.
Authority’s listing approval.
In addition to being approved for listing in China, Rexinto®'s global registration and application work is also being carried out simultaneously.
Currently, it has entered the new drug marketing application stage in the United States and is conducting key clinical studies in Europe. Build the world's leading microsphere technology platform to continuously improve the clinical benefits of patients
"The purpose of formulation innovation is to solve unmet clinical needs, covering various aspects such as efficacy, compliance, and side effects.
We pay attention to the experience and needs of patients, and are committed to providing differentiated and innovative products with clinical value to relieve patients.
We make unremitting efforts to improve the burden of disease and improve the clinical benefits of patients.
” said Mr.
Yang Rongbing, President of Luye Pharmaceutical Group.
Mr.
Yang Rongbing, President of Luye Pharmaceutical Group
Yang Rongbing, President of Luye Pharmaceutical Group
As one of the representatives of new high-end preparations, microsphere preparations are designed for the release speed and cycle according to clinical needs, and can continuously release the drug for a week to several months, and achieve the purpose of stable release of the drug, improved efficacy, and reduced side effects.
As a complex preparation, the development and production of microsphere preparations are difficult, and technical barriers are high.
This technology is mainly mastered by several foreign companies.
As a complex preparation, the development and production of microsphere preparations are difficult, and technical barriers are high.
This technology is mainly mastered by several foreign companies.
®，，。，、、，。，、。
，®。202111240，®。，，®，，。“®，，；01，，。” 。®，，，：（LY03003）、、（LY01005）、、 LY03009。®，，。
“，、、。，、，、。”。
“，、、。，、，、。”。
，，，，，。，、、，。
，，，，，。，、、，。®，，。，、、，。，、。
，®。202111240，®。，，®，，。“®，，；01，，。” 。®，，，：（LY03003）、、（LY01005）、、 LY03009。®，，。
®，，。，、、，。，、。
，®。202111240，®。，，®，，。“®，，；01，，。” 。®，，，：（LY03003）、、（LY01005）、、 LY03009。®，，。
